HONG KONG, Nov 6, 2020 - (ACN Newswire) - According to Bloomberg, recent years have seen the strong performance of biopharmaceutical enterprises in Hong Kong stock market. Bonnie Chan, Head of Listing of HKEX, said at the HKEX Biotech Summit on 1st September this year that 20 pre-revenue biotechnology companies had been listed in Hong Kong by then, raising a total of HK$48 billion in IPOs, and a total of HK$46 billion in post-IPO financing. The public offerings of BeiGene, Innovent Biologics and Junshi Biosciences have all expanded multiple times upon their IPO in their market value. With the listing of RemeGen next Monday, Hong Kong is to welcome another biotech superstar.Popular subscription and substantial room for rise in market value post IPOThe public offering of Ant Group last week froze a large amount of capital, posing pressure on other pre-listing companies. However, offering from RemeGen still gained great traction, with its institutional books hundreds multiple times covered and retail book over 50-time subscription in pool A and hundreds of times in pool B. With the sudden halt of Ant Group's IPO and hundreds of billions of funds being refunded to Hong Kong investors, ...